Drugs / YS-0N-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03131765 | Apr 2017 → Dec 2019 | cancer | Yisheng Biopharma (Singapore) Pte. Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | YS-0N-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03131765 ↗ |
| Modality | Vaccine | “Cancer vaccine” NCT03131765 ↗ |
| Route | Intramuscular | “vaccine administered intramuscularly (IM)” NCT03131765 ↗ |